DIRS.INFO The most relevant business & tech news

☆ Here are Friday's biggest analyst calls: Apple, Intel, Rivian, ResMed, Amazon, Enphase, Southwest & more
▼ + stars: | 2023-10-27 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

JPMorgan initiates TKO Group as overweight JPMorgan said the WWE and UFC combo company is a "sports champion." Bank of America downgrades Hasbro to neutral from buy Bank of America downgraded the toymaker after its earnings report on Thursday. " HSBC upgrades Intel to hold from sell HSBC upgraded Intel after its earnings report on Thursday. TD Cowen downgrades Southwest to market perform from outperform TD downgraded the stock after its "tough" earnings report on Thursday. " Goldman Sachs reiterates Amazon as buy Goldman said the stock remains attractive after its earnings report Thursday.

Persons: Cantor Fitzgerald, Rivian, Cantor, Stifel, we've, JPMorgan, Morgan Stanley, Piper Sandler downgrades, Piper, Guggenheim, Raymond James, Roblox, TD Cowen, TD Cowen downgrades Hershey, it's bullish, Wells, Goldman Sachs, Goldman Organizations: Dominion, WWE, UFC, " Bank of America, Hasbro, Bank of America, Products, Energy, JPMorgan, HSBC, Intel, Inc, Deutsche Bank, Deutsche, Griffon Corp, Management, Hershey, BMO, Merck, Citi, Cisco, JPMorgan downgrades, Apple, of America

☆ Here are Thursday's biggest analyst calls: Target, First Solar, Ford, Netflix, Amazon, Spotify, Exxon Mobil and more
▼ + stars: | 2023-10-12 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

Goldman Sachs reiterates Amazon as buy Goldman Sachs said it's standing by its buy rating ahead of earnings later this month. Citi reiterates Netflix as buy Citi said it's standing by its buy rating on the stock heading into earnings next week. Bank of America reiterates Ford as buy Bank of America said its standing by its buy rating on the stock despite the strike at Ford's largest truck plant. Bank of America upgrades Target to buy from neutral Bank of America said it sees an attractive risk/reward for Target shares. " RBC downgrades ResMed to sector perform from outperform RBC said in its downgrade of ResMed that it sees slowing earnings growth.

Persons: Warby Parker, BTIG, Goldman Sachs, Morgan Stanley, it's, JPMorgan, Bernstein, underperform Bernstein, CLX, Ford, Wells, Wells Fargo, Truist, it's bullish, D.A, Davidson Organizations: Citi, Netflix, 4Q23, Barclays, Spotify, Taiwan Semiconductor, JPMorgan, RBC, BMO, Bank of America, Ford's, UAW, Detroit, underperform Bank of America, 3Q, Microsoft, " Bank of America, of America, Exxon Mobil, Exxon, Pioneer, Seaport, Mizuho Locations: 2H24

☆ Stocks making the biggest moves midday: Walgreens, Birkenstock, Ford, Spotify and more
▼ + stars: | 2023-10-12 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Check out the companies making headlines in midday trading. Walgreens Boots Alliance — Walgreens Boots Alliance popped 7% in midday trading after sharing that it has made progress in its cost-cutting program. The German shoe brand fell more than 12% in its stock market debut Wednesday. First Solar — The solar stock slipped 1.4%. Fastenal posted third-quarter earnings of 52 cents per share, while analysts polled by FactSet anticipated 50 cents per share.

Persons: Morgan Stanley, it's, Fastenal, FactSet, — CNBC's Brian Evans, Lisa Kailai Han, Hakyung Kim, Samantha Subin, Darla Mercado Organizations: Walgreens, Walgreens Boots Alliance, LSEG, Spotify Technology, Bank of America, Microsoft, RBC, Barclays, Ford, United Auto Workers, Ford's, Revenue, Food, Commercial Workers International Union, Hormel Locations: Ford's Kentucky

☆ Australia's CSL tanks as Novo Nordisk's kidney trial success stokes competition concerns
▼ + stars: | 2023-10-12 | by ( Archishma Iyer | ) www.reuters.com time to read: +1 min

Oct 12 (Reuters) - Shares of biotechnology firm CSL (CSL.AX) fell to a four-year low on Thursday, after rival Novo Nordisk's (NOVOb.CO) Ozempic drug showed early signs of success in delaying the progression of kidney disease in diabetes patients. Shares of CSL closed 5.7% lower at A$239.77, their lowest since Oct. 10, 2019, after falling 6.7% earlier in the session. The stock also marked its worst intraday session in four months and was the top loser on the benchmark. CSL's Vifor segment, which includes therapies for kidney diseases and iron deficiencies, faces concerns of competition in the segment after Ozempic's early trial success, analysts said. Reporting by Archishma Iyer in Bengaluru; Editing by Varun H KOur Standards: The Thomson Reuters Trust Principles.

Persons: Novo, Shane Ponraj, Morningstar, Tim Waterer, Archishma Iyer, Varun Organizations: CSL, Novo Nordisk's, CSL Vifor, Novo Nordisk, KCM Trade, Sonic Healthcare, Thomson Locations: Danish, Bengaluru

☆ Stocks making the biggest moves premarket: Ford, Target, Walgreens, Domino's Pizza, First Solar and more
▼ + stars: | 2023-10-12 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

Target — The retailer rose 2.8% after Bank of America upgraded Target to buy from neutral. ResMed — The medtech device stock slipped 2% after a downgrade by RBC Capital Markets to sector perform from outperform. Plug Power — The battery stock added 1.2% after JPMorgan added the company to its positive catalyst watchlist, and highlighted potential near-term upside. First Solar — Stock in the solar panel maker added nearly 4% following an upgrade to overweight from Barclays, with analyst Christine Cho highlighting an attractive valuation. Domino's Pizza — Shares of the pizza delivery company slipped more than 3% on mixed third-quarter results.

Persons: ResMed, Christine Cho, Warby Parker, Janine Stichter, Jesse Pound, Michelle Fox, Pia Singh, Yun Li Organizations: Ford —, United Auto Workers, Target, Bank of America, Walgreens, Delta Air Lines, Delta, RBC Capital Markets, RBC, JPMorgan, Barclays, BTIG, BMO Capital Markets Locations: Kentucky, U.S

How GLP-1 drugs work Sorting through the facts reveals some likely winners and losers. LLY YTD mountain Eli Lilly shares year to date performance It is still early days for GLP-1 medications. Many have seen the rise of GLP-1 drugs as a threat to the medical device industry. Also, not all patients are able to tolerate GLP-1 drugs, which can cause side effects such as nausea. Among other medtech stocks, Plovanic sees GLP-1 drugs as an "incremental positive" for Dexcom, which makes continuous glucose monitors (CGMs), but an "incremental negative" for insulin pump makers like Insulet.

Persons: Insulet, Medtronic, Dexcom, BAX, NASH, Eli Lilly, Peter Verdult, Lilly, Eli Lilly aren't, Piper Sandler, Wegovy, Yasmeen Rahimi, Robbie Marcus, Marcus, hasn't, Baxter, David Low doesn't, William Plovanic, Craig Wong, Pan, Plovanic, Matt O'Brien, O'Brien, Rippling, Simeon Gutman, Morgan Stanley, Gutman, — CNBC's Michael Bloom Organizations: Novo Nordisk, Baxter International, Baxter, GLP, Citi, Novo, Bank of America, Viking Therapeutics, Pharmaceuticals, Pfizer, Amgen, Companies, Fisher, Reuters, Inspire, Systems, JPMorgan, RBC Capital, Walmart, underperformance Locations: GLP, U.S, DaVita, ResMed

☆ Stocks making the biggest premarket moves: Pioneer Natural Resources, Levi Strauss, Tesla, Philips and more
▼ + stars: | 2023-10-06 | by ( Michelle Fox | ) www.cnbc.com time to read: +2 min

Check out the companies making the biggest moves in premarket trading:Pioneer Natural Resources — The energy stock soared nearly 10% in premarket trading after The Wall Street Journal reported Pioneer was close to reaching a deal to be bought by Exxon Mobil for about $60 billion. Levi Strauss — The denim apparel maker shed 1.3% after cutting its full-year sales forecast. Apellis Pharmaceuticals — Shares of the biopharmaceutical company rose 5.5% after Apellis reported growing sales for its Syfovre drug in August. Aehr Test Systems — Shares fell more than 11% despite Aehr Test Systems reporting an earnings and revenue beat for its first quarter. Frontline — The shipping stock shed 4.8% in premarket trading after Euronav said its second shareholder, Compagnie Maritime Belge, would acquire Frontline's shares in Euronav for $18.43 per share.

Persons: Levi Strauss, Philips —, ResMed, Tesla, Euronav, Macheel, Jesse Pound Organizations: Resources, Street Journal, Exxon Mobil, Exxon, Philips, U.S . Food, Drug Administration, FDA, U.S, Apellis Pharmaceuticals, JPMorgan, Aehr, Systems, Compagnie Maritime Belge Locations: Dutch, U.S, Euronav

☆ The disruptive effect of weight loss drugs like Ozempic could have surprising impacts on the stock market. Here are potential winners and losers.
▼ + stars: | 2023-09-24 | by ( Matthew Fox | ) www.businessinsider.com time to read: +7 min

The potential ripple effects of GLP-1 weight loss drugs like Ozempic and Wegovy are far-reaching. These are the stock market's potential winners and losers of the fast-growing weight loss drugs. By contrast, typical weight loss without GLP-1 drugs is mostly driven by a reduction in fat, not muscle. AdvertisementAdvertisementFast-food chains and junk-food companiesMorgan Stanley surveyed 300 patients taking GLP-1 drugs and found that calorie intake dropped 20%-30% on a daily basis. AdvertisementAdvertisementBeer and tobacco companiesAnecdotes from patients taking GLP-1 drugs indicate that the drug helps curb certain addictive behaviors like smoking cigarettes or drinking alcohol.

Persons: Eli Lilly, Catalent, Fisher, McKesson, Baird, Jeff Johnson, Johnson, Morgan Stanley, Kreme, Morgan Stanley's, Phillip Morris Organizations: Service, Street, Novo Nordisk, JPMorgan, Nordisk, Bloomberg, Fitness, Nike, Inspire, Tandem Diabetes Care, KFC, Yum Brands, Anheuser, Busch, Molson Coors Locations: Wall, Silicon, GLP

☆ 'Mispriced' stocks like this solar name are too attractive to ignore, Bank of America says
▼ + stars: | 2023-09-23 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Earlier this week, however, the bank lifted its rating to buy from neutral, saying ESAB is too attractive to ignore. "In our view, ESAB is a mispriced asset and the discount to peers is likely to narrow with the upcoming [December] Investor Day as a catalyst," El-Sabbahy wrote. First Solar Analyst Julien Dumoulin-Smith is getting increasingly bullish on shares of the solar company. ESAB "ESAB is executing better than expected (leverage falling, margin expanding, growth outperforming) and we have a renewed appreciation of its portfolio. In our view, ESAB is a mispriced asset and the discount to peers is likely to narrow with the upcoming [December] Investor Day as a catalyst."

Persons: ESAB, Sherif El, Sabbahy, Julien Dumoulin, Smith, BofA, FSLR, Didier Scemama, ASML, Scemama, mgmt, RMD Organizations: of America, CNBC Locations: Swedish, GLP

New anti-obesity drugs have the potential to transform public health, while obliterating demand for products and services from the medical, food and fitness industries. Drugs developed by Novo Nordisk (NOVOb.CO) and Eli Lilly (LLY.N) appear to be the first truly effective diet treatments. In one clinical trial, patients taking Eli Lilly’s soon-to-be-launched weight-loss drug lost about 50 pounds (23 kg). Only about a third of those who started taking the drugs for obesity were still doing so a year later, according to one analysis. Yet even as Novo, Lilly and others see their addressable markets expand, some companies will see theirs shrink.

Persons: Lilly, George Frey, Eli Lilly, Eli Lilly’s, Novo, Wegovy, Kraft Heinz, Burger, LSEG, Michael Farrell, Zimmer Biomet, Smith, Peter Thal Larsen, Sharon Lam, Oliver Taslic Organizations: Novo Nordisk, Pharmacy, REUTERS, Reuters, TAM, Drugs, Alpha, Reuters Graphics Reuters, Cadbury, Mondelez, Fortune Business, Burger King, KFC, Yum Brands, Centers for Disease Control, Milken Institute, BMJ, Novo, Inspire Medical Systems, Novo Nordisk’s, WW International, Fashion, Thomson Locations: Provo , Utah, U.S, New, United States, Lilly, England

☆ Stocks making the biggest moves premarket: Enbridge, Roku, GitLab and more
▼ + stars: | 2023-09-06 | by ( Pia Singh | ) www.cnbc.com time to read: +4 min

Roku also lifted its third-quarter revenue guidance, saying it now expects revenue to range between $835 million and $875 million, versus prior guidance of $815 million. Along with the workforce reductions, Roku said it plans to consolidate office space and review its content slate to trim expenses. Zscaler posted adjusted earnings of 64 cents per share while analysts polled by LSEG, formerly known as Refinitiv, expected 49 cents. Additionally, the cybersecurity company said earnings and revenue should come in ahead of what analysts anticipate in the current quarter. GitLab — Shares of the technology platform jumped 6.5% in premarket trading following a strong second-quarter report postmarket Tuesday.

Persons: Roku, Zscaler, Needham, GitLab, LSEG, Asana, AeroVironment, Sam Subin, Michelle Fox Theobald, Jesse Pound Organizations: LSEG, Revenue, Dominion Energy, Dominion, UBS, Southwest Airlines —, Southwest, Novo Nordisk — Locations: Hastings, Hudson , New York, Enbridge, Dallas, Danish, Europe

☆ Here are Wednesday's biggest analyst calls: Nvidia, Apple, Tesla, Nio, SoFi, Amgen, Chewy, Toast and more
▼ + stars: | 2023-09-06 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

Here are Wednesday's biggest calls on Wall Street: UBS upgrades Toast to buy from neutral UBS said the restaurant tech company "continues to prove itself as a top provider" for the restaurant industry. " UBS downgrades Block to neutral from buy UBS said it sees slowing profit growth for Square's parent company. Deutsche Bank reiterates Nio as buy Deutsche Bank said it's concerned about the company's growth trajectory but that it's sticking with its buy rating. " Deutsche Bank reiterates Tesla as buy Deutsche Bank said it's standing by its buy rating on the auto giant. Bank of America reiterates SoFi as neutral The firm said SoFi is a key beneficiary of student loan refinances.

Persons: Baird, Goldman Sachs, William Blair, Argus, Russell, CFRA, it's, TD Cowen, Cowen, Morgan Stanley, Needham, Nio, Tesla, SoFi, refinances Organizations: UBS, omni, Nvidia, Technology, HSBC, Apple, Constellation Brands, Bloom Energy, Deutsche Bank, Bank of America

☆ How much is a good night's sleep worth? A lot to these stocks
▼ + stars: | 2023-09-04 | by ( Michelle Fox | ) www.cnbc.com time to read: +13 min

In fact, some 63% of U.S. adults sleep less than the recommended seven to nine hours a night, according to the National Sleep Foundation's Sleep Health Index. There are a myriad of products in the sleep arena — from mattresses and sleep supplements to sleep apnea devices and tech wearables that track sleep. Treating sleep conditions Health conditions can also impact the ability to get a good night's rest, like insomnia and sleep apnea. Obstructive sleep apnea causes breathing to be interrupted during sleep. About half of those surveyed in its obstructive sleep apnea patient survey in July said they had never heard of Inspire.

Persons: Anna Pione, they'll, Seth Basham, Basham, Tempur Sealy, " Basham, It's, Stefano Natella, Natella, it's, Ollie, Seamus Fernandez, Philip's, Philips, Eli Lilly, Eli Lilly's, Guggenheim's Fernandez, Michael Farrell, we've, Fernandez, Novo, wearables, Gene Munster, Jason Ware, Ware, Pione, Michael Bloom Organizations: McKinsey, International Sleep Products, Sealy International, Mattress, Sealy, Centers for Disease Control, Guggenheim, CDC, Unilever, American, of, Care, American Medical Association, Bank of America Securities, Medical Systems, Bank of America, Inspire, Novo Nordisk, Garmin, Apple, Deepwater Asset Management, Apple Watch, Albion Financial, Munster Locations: U.S, dreamland, Mizuho, Novo

☆ As weight loss drug stocks rallied on a landmark study, these stocks were over sold, analysts say
▼ + stars: | 2023-08-11 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +8 min

However, the pharmaceutical companies are making the case that weight loss can improve health, and possibly lower health-care costs over time. But analysts have said the news isn't all bad for such stocks, and many were fell too low on Tuesday. Deutsche Bank analyst Imron Zafar estimated Thursday that bariatric surgery accounts for about 5% of Intuitive Surgical's U.S. robotic surgery business, but has been driving much of the company's growth. Some of the surgeons Zafar spoke with said any drop off in bariatric surgery was likely to be offset by increased use of the robot for other procedures. But they expect the drugs will remain necessary because GLP-1 drugs have yet to show they improve fibrosis, which is associated with NASH.

Persons: nonalcoholic steatohepatitis, NASH, Abbott, Robbie Marcus, Marcus, Marcus doesn't, Goldman Sachs, Goldman, Stryker, Smith, Zimmer Biomet, Bariatric, Imron Zafar, Zafar Organizations: Novo Nordisk, Abbott Laboratories, CNBC, JPMorgan, Companies, Inspire Medical Systems, Resmed, Philips, Nephew, Deutsche Bank, Madrigal Pharmaceuticals, Sagimet Biosciences, Akero Therapeutics, Terns Pharmaceuticals, Viking Therapeutics, Madrigal Locations: U.S

☆ Stocks making the biggest moves midday: Coinbase, SoFi, DoorDash and more
▼ + stars: | 2023-08-01 | by ( Hakyung Kim | ) www.cnbc.com time to read: +5 min

DoorDash — Shares tumbled about 4% ahead of the company's quarterly earnings announcement Wednesday after the bell. Despite reporting better-than-expected earnings and revenue in the second quarter, its third-quarter revenue guidance was lower than analysts were expecting. Leidos Holdings — The defense solutions company's shares rallied 6.7% after its second-quarter results topped analyst estimates. Eaton Corporation — The power management company's shares increased 5.6% after beating analyst expectations on both earnings and revenue in the second quarter. Meanwhile, analysts had estimated $2.59 earnings per share on $2.19 billion in revenue, according to FactSet.

Persons: Refinitiv, ResMed, Adrienne Yih, Leidos, FactSet, — CNBC's Alexander Harring, Yun Li, Pia Singh, Tanaya Macheel, Michelle Fox, Sarah Min Organizations: Toyota, Securities, SEC, RBC, Barclays, JetBlue Airways –, American Airlines, Technologies, Cruise Line Holdings, Norwegian Cruise Line, Rockwell Automation, Systems, Molson Coors Beverage —, StreetAccount, Leidos Holdings, Eaton Corporation, Global Payments Locations: San Diego , U.S, Manhattan, Monday's, FactSet

☆ Here are Tuesday's biggest analyst calls: Apple, Tesla, Amazon, Gap, Target, PayPal, Coinbase & more
▼ + stars: | 2023-08-01 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Morgan Stanley reiterates Tesla as equal weight Morgan Stanley said in its annual ask the interns survey that Tesla favorability fell. " Morgan Stanley reiterates PayPal as overweight Morgan Stanley said it's bullish heading into PayPal earnings on Wednesday. " Oppenheimer reiterates Target as outperform Oppenheimer said investors should buy the dip ahead of Target earnings later this month. Bank of America reiterates DraftKings as buy Bank of America is bullish heading into earnings later this week. Morgan Stanley reiterates Ford as overweight Morgan Stanley said it's standing by its overweight rating, but that the company needs an electric vehicle strategy change soon.

Persons: Baird, it's, Cantor Fitzgerald downgrades Rivian, Cantor, Morgan Stanley, Tesla, Read, RMD, PYPL, Oppenheimer, Canaccord, Estee Lauder, DraftKings, DoorDash, comps, Bernstein, Goldman Sachs, Goldman, Ford Organizations: Apple, Mercedes, Barclays, 2H23, RBC, PayPal, Citi, EL, Amazon, Bank of America, Anheuser, Busch InBev, Goldman, Meta Locations: US

☆ An investment chief who manages $1 billion in assets shares 10 investments that will reduce your portfolio's volatility while this bear market lasts longer than expected.
▼ + stars: | 2023-05-03 | by ( James Faris | ) www.businessinsider.com time to read: +5 min

Here are 10 ways to protect against losses and volatility in this long-lasting bear market. "It went beyond dodging a bullet," Steve Sosnick, the chief strategist at Interactive Brokers, said of first quarter earnings results in a late April interview with Insider. Weaker earnings raise valuation concernsBut some investors aren't impressed by Q1 earnings — at least not enough to get bullish. Besides weaker earnings growth and lofty valuations, another risk for stocks is that upcoming quarterly results will miss higher expectations in a shaky economy. "We're still looking at fairly high-single-digit earnings growth for the next couple of quarters overall," Sosnick said.

☆ ResMed CEO Mick Farrell goes one-on-one with Jim Cramer to discuss quarterly results
▼ + stars: | 2023-05-01 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

ResMed CEO Mick Farrell goes one-on-one with Jim Cramer to discuss quarterly resultsResMed CEO Mick Farrell joins 'Mad Money' host CEO to discuss quarterly growth, supply chain issues, and the companies outlook for the future.

By comparison, less than 5% of companies mentioned AI in analyst calls held during the first quarter of 2016. Big Tech mentions jump AI has been a growing theme in Big Tech as companies try to capitalize on the wave following 2022's selloff. In calls from Big Tech companies alone, AI was mentioned 265 times. Executives at real estate company UDR said its AI chat has a 10% higher closing rate than normal call centers. Interpublic Group of Companies CEO Philippe Krakowsky noted the advertising company brought on a chief AI officer two years ago.

☆ Check out these 12 digital-health startups that could be acquisition targets in 2023 as founders seek IPO alternatives, according to Dealroom data
▼ + stars: | 2023-04-17 | by ( Riddhi Kanetkar | ) www.businessinsider.com time to read: +3 min

Insider has identified 12 digital-health startups that are M&A targets in 2023 with Dealroom data. Dealmaking remains strong among healthtech startups in the region, which recorded $13.27 billion in M&A exits in 2022 across 546 deals, according to PitchBook data. Insider has used data from Dealroom to analyze potential M&A targets in the digital-health sector. The criteria used on Dealroom's platform are not exhaustive but are a data-centric approach to looking at some potential targets. Here is a list of the 12 digital-health startups that could be scooped up as investors flock to the M&A market.

☆ This maker of CPAP machines can gain market share as rival deals with a recall, Mizuho says
▼ + stars: | 2023-04-14 | by ( Brian Evans | ) www.cnbc.com time to read: +1 min

An ongoing product recall for one of ResMed's top competitors opens up a big opportunity for the continuous positive airway pressure (CPAP) equipment maker, according to Mizuho. Philips Respironics, a rival CPAP hardware maker, is still contending with a 2021 recall of its products, leaving the door open for ResMed to grow its market share, Petrone said. "In aggregate, we see RMD settling at nearly ~60% permanent sleep device share, up from ~50%, as a result of the extended Philips CPAP recall," Petrone wrote on Thursday. Petrone added that ResMed has maintained its market share from a decline in Philips for longer than expected. RMD YTD mountain RMD in 2023 Mizuho pointed toward proprietary survey data that indicated pent-up demand and a rebound in U.S. volume.

☆ Here are Friday's biggest analyst calls: Amazon, VF Corp, Deere, Netflix, Rivian, Nvidia & more
▼ + stars: | 2023-04-14 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are Friday's biggest calls on Wall Street: Bank of America reiterates Amazon as buy Bank of America said it's standing by its buy rating on the stock. "Our Buy rating is based on: 1) positive feedback from our proprietary Sleep survey that points to healthy underlying US volumes, 2) lingering pent-up demand due to US staffing shortages." William Blair reiterates Charles Schwab as outperform William Blair said it's standing by its outperform rating on the stock heading into earnings next week. Barclays reiterates Disney as equal weight Barclays said it sees slowing streaming growth heading into Disney earnings in early May. " Stifel reiterates Microsoft as buy Stifel said it's standing by its buy rating on Microsoft heading into earnings later this month.

As another earnings season picks up, Bank of America says investors may find upside opportunities in certain underowned stocks that could beat expectations. The SPDR S & P Regional Banking ETF has tumbled 27.1% so far this year. Medical device maker Resmed also made the list, with a z-score of 0.8 and relative weight value of 0.1. The stock's relative weight in fund holdings versus the broad market index is 0.1. The Bermuda-based insurance group's relative weight in active fund holdings, versus the S & P 500, is 0.6.

☆ A top GE HealthCare marketing exec reveals the brand strategy that helped the GE spinoff become a $35 billion company two months after going public
▼ + stars: | 2023-03-13 | by ( Lauren Johnson | ) www.businessinsider.com time to read: +3 min

GE HealthCare built a brand campaign that helped the company hit a $35 billion marketing cap. In January, GE HealthCare started publicly trading as its own business, and it now has a market cap value of $35 billion. GE HealthCare launched an ad campaign created by BBDO on January 4, the day of the spinoff. GE HealthCare is also building a social presence, mostly focused on LinkedIn. "It was a brilliant move because the GE brand stands for innovation, thinking differently, and creating dialogue," Fallon said.

☆ Bank of America just added these biotech stocks to its list of first-quarter picks
▼ + stars: | 2023-01-09 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

BofA has added a number of biotechnology stocks — a sector that is hot on Wall Street right now – to its list of top picks for the first quarter. The bank identified the biotech stocks, as well as some medical technology companies, as part of its thematic investing picks, on themes it says are related to a "transforming world." BofA listed the stocks under themes such as ageing, obesity and pandemic. The bank added biotech firm BioNTech , as well as medical equipment company ResMed , to its list under this theme. The bank added medical technology firm Silk Road Medical , along with biotech firms Cerevel and Denali , to its list of stocks to play this theme.

Search resuls for: "ResMed"

25 mentions found